FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPRO	OVAL			
OMB Number:	3235-0287			
Estimated average burd	en			
hours per response:	0.5			

1. Name and Address of Reporting Person* Young David (Last) (First) (Middle) 1300 NORTH KELLOGG DRIVE SUITE D						QUESTCOR PHARMACEUTICALS INC [QCOR] 3. Date of Earliest Transaction (Month/Day/Year) 02/24/2013										ationship of Reporting Person(s) to Issuer & All applicable) Director 10% Owner Officer (give title Other (specify below) below) Chief Scientific Officer			
(Street) ANAHE	IM CA		92807 (Zip)												ne) <mark>X</mark> For For	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person			
		Tabl	le I - No	n-Deriv	ative	Se	curitie	s Acc	quired,	Dis	posed o				ally Own	ed			
				2. Transaction Date (Month/Day/Year)		ır) E	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Transaction Code (Instr.					d Secu Bene	ficially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount		A) or D)	Price	Trans	action(s) 3 and 4)		(1130.4)	
Common Stock ⁽¹⁾					24/2013				A		21,332	(2)	Α	\$)	35,235	D		
Common Stock ⁽¹⁾					2/24/2013				A		25,000	(3)	A	A \$0		60,235			
Common Stock ⁽¹⁾					02/24/2013				A		25,000	(4)	A	\$		35,235	D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	ive Conversion Date Execution y or Exercise (Month/Day/Year) if any		n Date,	4. Transaction Code (Instr. 8)		of Derive Secue Acque (A) or Disposof (D) (Instr	of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Date Exercisable a Expiration Date Month/Day/Year) Date Expirat Exercisable Date			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amount or Numbe of Title Shares		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		

Explanation of Responses:

- $1.\ Restricted\ stock\ granted\ under\ the\ Questcor\ Pharmaceuticals,\ Inc.\ 2006\ Equity\ Incentive\ Award\ Plan.$
- 2. Represents a restricted stock award in connection with the Company's 2012 incentive compensation policy that provides for the vesting of 100% of shares one year from the date of grant.
- $3.\ Represents\ a\ restricted\ stock\ award\ that\ vests\ in\ four\ equal\ annual\ installments\ beginning\ on\ 2/24/2014.$
- 4. Represents a restricted stock award that vests subject to the achievement of certain performance-based criteria.

<u>/s/ David Young</u> <u>02/26/2013</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.